Dapagliflozin 10mg (Dapagliflozin)
Dapagliflozin 10mg
Tablet · Prescription medication
Aprogen Pharmaceuticals Co., Ltd.
MFDS item code 202004459 · Approved 2020.06.17
This product's status changed to Expired on 2025.06.17. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improves blood glucose control in type 2 diabetes mellitus
This drug is used as an adjunct to diet and exercise to help control blood sugar in patients with type 2 diabetes. It can be administered as monotherapy when blood sugar control is difficult, and can be used in conjunction with other diabetes medications such as Metformin, Sulfonylureas, Insulin, and Sitagliptin as needed. In particular, this drug can be added to achieve effective blood sugar control in situations where monotherapy or existing treatment does not sufficiently control blood sugar. This approach helps improve blood sugar control and assists in diabetes management.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10 mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received pharmacological treatment for diabetes, the recommended initial dose of this medicine when administered in combination with metformin is 5 mg once daily or 10 mg once daily. Special populations Renal impairment - eGFR below 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dosage adjustment is necessary for patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, an initial dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dosage adjustment based on age is not recommended. Method of administration This medicine may be taken orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.
This drug should not be used in patients who are allergic to the active ingredient or excipients. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. It contains anhydrous lactose, so patients with genetic conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not use it. This drug should not be administered to patients undergoing dialysis. Patients with decreased fluid volume or impaired kidney function should have their fluid status and kidney function thoroughly evaluated before administration, and after administration, symptoms of hypotension and changes in kidney function should be closely monitored. For patients with moderate to severe kidney function impairment, blood sugar control efficacy may decrease, and it is not recommended for patients with eGFR below 45 mL/min/1.73m² for blood sugar control purposes. This drug may increase the risk of genital infections and urinary tract infections, so treatment should be sought immediately if symptoms of infection occur. There is a risk of hypoglycemia, so dose adjustments may be necessary when taken with insulin or Sulfonylureas. Dehydration and hypotension due to decreased fluid volume may occur, so special caution should be taken, particularly for elderly patients or those on diuretics. Diabetic ketoacidosis may occur, so if metabolic acidosis symptoms arise regardless of blood sugar levels, immediate testing and treatment are required. Elderly patients have a higher risk of changes in kidney function and decreased fluid volume, so careful monitoring is essential. Pregnant or breastfeeding women should not use this drug, and treatment should be discontinued when pregnancy is confirmed. There is no specific antidote for overdose, but appropriate treatment should be received based on symptoms, and it is unknown whether the drug is removed by dialysis. This drug does not significantly affect the ability to drive or operate machinery, but awareness of hypoglycemia symptoms is necessary.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly sealed container to prevent exposure to air and moisture. The storage temperature should be maintained between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness for a longer duration.
Yellow, double-convex, diamond-shaped film-coated tablet
8 tablets/Blister, 100 tablets/Bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin 10mg
Tablet · Prescription medication
Aprogen Pharmaceuticals Co., Ltd.

Dapagliflozin 10mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Dapagliflozin 5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Dapagliflozin 10mg
Tablet · Prescription medication
Jongkundang Co., Ltd.
Dapagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharma Co., Ltd.
Dapagliflozin 10mg
Tablet · Prescription medication
Withus Pharmaceutical Co., Ltd.
Dapagliflozin 10mg
Tablet · Prescription medication
IYUN Pharmaceutical Co., Ltd.
Dapagliflozin 10mg
Tablet · Prescription medication
Litepharmtech Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.